ナミキ商事株式会社 医薬品及び創薬化学品の専門商社

医薬品及び創薬化学品の専門商社

検索検索

新着情報News

【TargetMol】抗がん剤ライブラリのご紹介

  • 2025/04/16
  • サプライヤニュース

新着情報一覧へ

 
 

Enhance Your Oncology Research with Our Anti-Cancer Drug Library

Anticancer compounds refer to chemical substances that can inhibit the growth and proliferation of cancer cells or induce cancer cell apoptosis. These compounds achieve cancer treatment by interfering with biological processes of cancer cells, such as DNA replication, cell division, and signal transduction. Anticancer compounds can be derived from natural sources or artificially synthesized, encompassing various types, including small-molecule drugs, biologics, and antibody drugs.

 

 

TargetMol has carefully selected 1800 approved anti-cancer drugs based on published literatures and database to form this collection that can be used as positive controls in biological cancer investigation and cancer correlation study.

 

Application

 

1. Accelerating New Drug Development and Optimization
Targeted Drug Design

Targeted drugs from Anti-Cancer Approved Drug Library provide templates for novel drug development. For instance, YL201 employs the TMALIN technology, enabling a tumor microenvironment-activated dual-release mechanism that significantly enhances efficacy while reducing toxicity, offering new insights into solid tumor treatment.

AI-Assisted Drug Screening

Combining data from this library with AI technology accelerates target discovery and compound optimization. For example, Transformer models is utilized to analyze TCR-antigen matching, reducing the new drug development cycle from 36 months to just 6 months.

 

2. Advancing Combination Therapy Development

Combination of Immunotherapy and Targeted Drugs
For example, Envafolimab combined with chemotherapy for EGFR-mutant lung cancer has achieved a median overall survival (OS) of 22.5 months.

Combination of Chemotherapy and Anti-angiogenic Drugs
For instance, the Camrelizumab+ Apatinib for treatment of liver cancer has demonstrated a median overall survival (OS) of 22.1 months, reducing the risk of disease progression by 48%.

 

3. Supporting Basic Research and Translational Medicine

Research on Tumor Microenvironment

Approved drug libraries containing immune checkpoint inhibitors help elucidate tumor immune evasion mechanisms.

For example, Serplulimab  inhibits the PD-1 pathway, reducing the risk of death in small cell lung cancer patients by 38%.

 

Hot-selling Cancer-related Compound Libraries
Catalog No. 
Product Name
TargetMol Link
Contact Us!
If you are interested in those products and get information on our more products,please visit our website:https://www.targetmol.com or contact us at sales@targetmol.com for possible discounts!
 
 
 
Linkedin
 
 
 
 
Facebook
 
 
 
 
Newsletter
 
 
 

TargetMol(ターゲットモル)社について

本社所在地
アメリカ マサチューセッツ州
URL
https://www.targetmol.com/

TargetMolは、ボストンに本社を置く低分子およびスクリーニングライブラリのサプライヤです。ライフサイエンス試薬、阻害剤、活性剤、実験用および科学用の天然化合物を提供しています。ポートフォリオには、6,000を超える化合物/阻害剤(カタログ)と80種類を超える化合物ライブラリがあります。

ご不明点等ございましたら、お気軽にお問い合わせください。

お問い合わせ